MAT^®  treatment

  Metabolic Activation Therapy   

  Home 

MAT® treatment

Clinics 

  Treatment  Results

 Physiology

 Research

 Legal

Contact Us

Research studies

These studies,  published by Dr. Aoki and others, demonstrate the effects of the therapy now called MAT^® treatment.  Over the years the treatment acquired several different names, chronic intermittent intravenous insulin therapy (CIIIT), metabolic activation therapy (MAT ), pulsatile insulin,  pulse insulin therapy (PIT), pulsatile intravenous insulin therapy (PIVIT) and hepatic activation.  All the publications below refer to the same treatment now called MAT^®.                 

A pilot study to test the effect of pulsatile insulin infusion on cardiovascular mechanisms that might contribute to attenuation of renal compromise in type 1 diabetes mellitus patients with proteinuria.  Weinrauch LA, Burger AJ, Aepfelbacher F, Lee AT, Gleason RE, D'Elia JA.  Metabolism. 2007 Nov;56(11):1453-7.

Chronic intermittent intravenous insulin therapy: a new frontier in diabetes therapy  Aoki TT, Grecu EO, Arcangeli MA, Benbarka MM, Prescott P, Ahn JH. Diabetes Technol Ther. 2001 Spring;3(1):111-23. Review.

Effects of pulsatile intravenous insulin therapy on the progression of diabetic nephropathy.  Dailey GE, Boden GH, Creech RH, Johnson DG, Gleason RE, Kennedy FP, Weinrauch LA, Weir M, D'Elia JA.  Metabolism. 2000 Nov;49(11):1491-5.

Effect of intensive insulin therapy on progression of overt nephropathy in patients with type 1 diabetes mellitus.  Aoki TT, Grecu EO, Gollapudi GM, Barber AR, Arcangeli MA, Benbarka MM, Prescott P, Meisenheimer R. Endocr Pract. 1999 Jul-Aug;5(4):174-8.

Long-term intermittent intravenous insulin therapy and type 1 diabetes mellitus.  Aoki TT, Benbarka MM, Okimura MC, Arcangeli MA, Walter RM Jr, Wilson LD, Truong MP, Barber AR, Kumagai LF.  Lancet. 1993 Aug 28;342(8870):515-8.

Effect of chronic intermittent intravenous insulin therapy on antihypertensive medication requirements in IDDM subjects with hypertension and nephropathy.  Aoki TT, Grecu EO, Prendergast JJ, Arcangeli MA, Meisenheimer R.  Diabetes Care. 1995 Sep;18(9):1260-5.

Effect of intensive insulin therapy on abnormal circadian blood pressure pattern in patients with type I diabetes mellitus  Aoki TT, Grecu EO, Arcangeli MA, Meisenheimer R.Online J Curr Clin Trials. 1995 Dec 15;Doc No 199:

Chronic intermittent intravenous insulin therapy corrects orthostatic hypotension of diabetes  Aoki TT, Grecu EO, Arcangeli MA.Am J Med. 1995 Dec;99(6):683-4.

Role of muscle in CO2 production after oral glucose administration in man.   Meistas MT, Vlachokosta FV, Gleason RE, Arcangeli M, Aoki TT.  Diabetes. 1985 Oct;34(10):960-3.

Evidence for restoration of hepatic glucose processing in type I diabetes mellitus.  Aoki TT, Vlachokosta FV, Foss MC, Meistas MT.  J Clin Invest. 1983 Apr;71(4):837-9.

Restoration of glucose homeostasis in insulin-dependent diabetic subjects. An inducible process.  Foss MC, Vlachokosta FV, Cunningham LN, Aoki TT.  Diabetes. 1982 Jan;31(1):46-52.

 IGF-1 and IGFBP-1 blood levels in type 1 diabetes mellitus on intensive intravenous insulin therapy.  Aoki TT, Grecu EO.  J Invest Med, 1999; 47(2) 78 A.  (abstract)